Pka Riiβ Protein (Protein Kinase A Regulatory Subunit 2B) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| Protein Name | PKA RIIβ (Protein Kinase cAMP-Dependent Regulatory Subunit Type II Beta) |
|---|---|
| Gene | [PRKAR2B](/genes/prkar2b) |
| UniProt ID | [P31321](https://www.uniprot.org/uniprot/P31321) |
| PDB ID | 1R2A, 2Q0J, 4DG0 |
| Molecular Weight | 45.5 kDa |
| Subcellular Localization | Cytoplasm, Synapse, Nucleus |
| Protein Family | cAMP-Dependent Protein Kinase Regulatory Subunit Family |
PKA RIIβ is the neuron-specific regulatory subunit of protein kinase A (PKA). The RIIβ-containing PKA is particularly important in the brain, where it regulates synaptic plasticity, memory formation, and tau phosphorylation.
PRKAR2B is a 404-amino acid regulatory subunit:
Research on PKA RIIβ in neurodegeneration focuses on understanding its role in tau phosphorylation and synaptic plasticity. Studies have shown that RIIβ-containing PKA holoenzymes are particularly important for memory consolidation, making them attractive targets for AD therapeutics[6]. Selective RIIβ modulators are being developed to enhance PKA activity in neurons while minimizing peripheral side effects.
The connection between RIIβ dysfunction and circadian rhythm disturbances in neurodegenerative diseases is an emerging research area. Given the role of PKA in circadian clock gene expression, RIIβ may provide a mechanistic link between circadian disruption and neurodegeneration[7].
The study of Pka Riiβ Protein (Protein Kinase A Regulatory Subunit 2B) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
PKA RIIβ is being explored as a therapeutic target:
RIIβ expression may serve as a biomarker:
Future research priorities: